Printer Friendly

ENDOTRONICS, INC. ANNOUNCES PURCHASE OF OPTICELL(TM) CELL CULTURE PRODUCT LINE FROM CHARLES RIVER LABORATORIES

 ENDOTRONICS, INC. ANNOUNCES PURCHASE OF OPTICELL(TM)
 CELL CULTURE PRODUCT LINE FROM CHARLES RIVER LABORATORIES
 MINNEAPOLIS, July 7 /PRNewswire/ -- Endotronics, Inc. (NASDAQ: ENDO) announced today it has purchased the OPTICELL(TM) Cell Culture System product line from Charles River Laboratories, a subsidiary of Bausch & Lomb (NYSE: BOL). The OPTICELL product line utilizes cell culture technology which is complementary to Endotronics' ACUSYST(R) hollow fiber technology, providing the bioprocessing market with an alternative to hollow fiber technology for use in production of diagnostic and therapeutic drugs.
 Richard E. Sakowicz, president and chief operating officer of Endotronics, said, "By acquiring this product line, Endotronics has become one of the first companies to offer customers alternative cell culturing technologies. The OPTICELL system is configured for growth of both suspension and anchorage-dependent mammalian cells. We believe the OPTICELL technology will be particularly suited for the large vaccine market, the market for which the OPTICELL technology was originally designed."
 Endotronics, Inc., headquartered in Minneapolis, is dedicated to providing cell processing products and services to meet the needs of human health care and biotechnology markets worldwide. The company is a recognized leader in hollow fiber cell culture instrumentation with more than 675 instruments installed worldwide.
 -0- 7/7/92
 /CONTACT: Yvonne L. Marschner-Bova, director, investor relations, Endotronics, Inc., 313-871-7350/
 (ENDO BOL) CO: Endotronics, Inc.; Charles River Laboratories; Bausch & Lomb ST: Minnesota IN: MTC SU: TNM


SM -- DE008 -- 6963 07/07/92 11:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 7, 1992
Words:238
Previous Article:AT&T TO PROVIDE MEDIA COMMUNICATIONS CENTER FOR DEMOCRATIC NATIONAL CONVENTION
Next Article:TWO DIRECTORS JOIN SEALRIGHT BOARD
Topics:


Related Articles
ENDOTRONICS SIGNS PRODUCTION AND MARKETING AGREEMENT WITH HELIXYS
ENDOTRONICS RECEIVES JAPANESE PATENT ON CELL CULTURE TECHNOLOGY
ENDOTRONICS, INC. RECEIVES EUROPEAN PATENT ON SCALABLE OXYCELL CELL CULTURE TECHNOLOGY
ENDOTRONICS, INC. ANNOUNCES RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED JUNE 30, 1992
ENDOTRONICS REPORTS FOURTH-QUARTER AND FISCAL 1992 YEAR-END RESULTS
ENDOTRONICS, INC. UPGRADES PRODUCTION FACILITY AND SIGNS CYTOGEN CORPORATION CONTRACT
ENDOTRONICS REPORTS RESULTS FOR ITS FIRST QUARTER ENDED DEC. 31, 1992
ENDOTRONICS, INC. ANNOUNCES REALIGNMENT; HORWATH PROMOTED TO VICE PRESIDENT AND GENERAL MANAGER OF BIOPROCESSING BUSINESS UNIT
ENDOTRONICS, INC. PURCHASES VERAX CORPORATION PRODUCT LINE
BIOWHITTAKER ACQUIRES PRODUCT LINES

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters